(NASDAQ: XERS) Xeris Biopharma Holdings's forecast annual revenue growth rate of 16.29% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.1%.
Xeris Biopharma Holdings's revenue in 2024 is $163,914,000.On average, 5 Wall Street analysts forecast XERS's revenue for 2024 to be $25,884,450,340, with the lowest XERS revenue forecast at $24,818,127,619, and the highest XERS revenue forecast at $27,276,063,291. On average, 5 Wall Street analysts forecast XERS's revenue for 2025 to be $30,714,925,977, with the lowest XERS revenue forecast at $27,416,516,758, and the highest XERS revenue forecast at $32,360,478,797.
In 2026, XERS is forecast to generate $36,335,592,820 in revenue, with the lowest revenue forecast at $33,849,285,547 and the highest revenue forecast at $37,891,536,327.